The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes
Abstract
Information on the molecular distribution and ageing trend of brain iron in post-mortem material from normal subjects is scarce. Because it is known that neuromelanin and ferritin form stable complexes with iron(III), in this study we measured the concentration of iron, ferritin and neuromelanin in substantia nigra from normal subjects, aged between 1 and 90 years, dissected post mortem. Iron levels in substantia nigra were 20 ng/mg in the first year of life, had increased to 200 ng/mg by the fourth decade and remained stable until 90 years of age. The H-ferritin concentration was also very low (29 ng/mg) during the first year of life but increased rapidly to values of approximately 200 ng/mg at 20 years of age, which then remained constant until the eighth decade of life. L-Ferritin also showed an increasing trend during life although the concentrations were approximately 50% less than that of H-ferritin at each age point. Neuromelanin was not detectable during the first year, increased to approximately 1000 ng/mg in the second decade and then increased continuously to 3500 ng/mg in the 80th year. A Mössbauer study revealed that the high-spin trivalent iron is probably arranged in a ferritin-like iron--oxyhydroxide cluster form in the substantia nigra. Based on this data and on the low H- and L-ferritin content in neurones it is concluded that neuromelanin is the major iron storage in substantia nigra neurones in normal individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the substantia nigra, ferritin heavy chain and ferritin light chain concentrations increase with age, whereas these are constant in the locus coeruleus; therefore iron could contribute to neurodegeneration in the substantia nigra more than in the locus coeruleus.5,6”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [5]
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 850
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
Sofic, E., Riederer, P. F., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G. F., & Youdim, M. B. H. (1988) · Journal of Neural Transmission · doi:10.1007/bf01244786 · Cited by 754
Aging and Extrapyramidal Function
McGeer, P. L., McGeer, E. G., & Suzuki, J. S. (1977) · Archives of Neurology · doi:10.1001/archneur.1977.00500130053010 · Cited by 648
Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains
Connor, J. R., Menzies, S. L., Martin, S. M. S., & Mufson, E. J. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490270421 · Cited by 472
Research works printed but not linked: 2
- Moos T., 2000, Absence of ferritin protein in substantia nigra pars compacta neurons. A reappraisal to the role of iron in Parkinson disease pathogenesis, Mov. Disord., 15, 319A
- Zareba M., 1995, The effect of synthetic neuromelanin on yeld of free hydroxyl radicals generated in model system, Biochim. Biophys. Acta, 1138, 6
Cited by
Sorted by citations
The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
The physical and chemical properties of eumelanin
Meredith, P., & Sarna, T. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00345.x · Cited by 1,033
Kell, D. B., & Pretorius, E. (2014) · Metallomics · doi:10.1039/c3mt00347g · Cited by 667
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
Self-citationGenetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 594
Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R. G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403495101 · Cited by 495
Protective and toxic roles of dopamine in Parkinson's disease
Segura‐Aguilar, J., Paris, I. B., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12686 · Cited by 517
Biological metals and metal-targeting compounds in major neurodegenerative diseases
Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497
Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells
Crichton, R. R., Wilmet, S., Legssyer, R., & Ward, R. J. (2002) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(02)00461-0 · Cited by 494
Ferroptosis and Its Role in Diverse Brain Diseases
Weiland, A., Wang, Y., Wu, W., Lan, X., Han, X., Li, Q., & Wang, J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1403-3 · Cited by 473
Pang, S. Y.-Y., Ho, P. W., Liu, H., Leung, C.-T., Li, L., Chang, E. E. S., Ramsden, D. B., & Ho, S. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0165-9 · Cited by 457
The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy
Gaeta, A., & Hider, R. C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706416 · Cited by 411
Brain iron pathways and their relevance to Parkinson's disease
Berg, D., Gerlach, M., Youdim, M. B. H., Double, K. L., Zecca, L., Riederer, P., & Becker, G. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00608.x · Cited by 362
Hong, L., & Simon, J. D. (2007) · The Journal of Physical Chemistry B · doi:10.1021/jp071439h · Cited by 360
Metals and amyloid‐β in Alzheimer's disease
Maynard, C. J., Bush, A. I., Masters, C. L., Cappai, R., & Li, Q. (2005) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2005.00434.x · Cited by 356
Maynard, C. J., Cappai, R., Volitakis, I., Cherny, R. A., White, A. R., Beyreuther, K. T., Masters, C. L., Bush, A. I., & Li, Q. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204379200 · Cited by 352
The relevance of iron in the pathogenesis of Parkinson’s disease
Sian‐Hülsmann, J., Mandel, S. A., Youdim, M. B. H., & Riederer, P. F. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07132.x · Cited by 364
Fedorow, H., Tribl, F., Halliday, G. M., Gerlach, M., Riederer, P. F., & Double, K. L. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.001 · Cited by 347
The Relevance of Iron in the Pathogenesis of Parkinson's Disease
Götz, M. E., Double, K. L., Gerlach, M., Youdim, M. B. H., & RIEDERERE, P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.017 · Cited by 343
Wilms, H., Rosenstiel, P. C., Sievers, J., Deuschl, G., Zecca, L., & Lucius, R. (2003) · The FASEB Journal · doi:10.1096/fj.02-0314fje · Cited by 337
Iron in Neurodegeneration – Cause or Consequence?
Ndayisaba, A., Kaindlstorfer, C., & Wenning, G. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00180 · Cited by 305
Zecca, L., Fariello, R. G., Riederer, P. F., Sulzer, D. L., Gatti, A., & Tampellini, D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03269-0 · Cited by 287
Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics
Duce, J. A., & Bush, A. I. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.003 · Cited by 288
Wang, Y., Spincemaille, P., Liu, Z., Dimov, A., Deh, K., Li, J., Zhang, Y., Yao, Y., Gillen, K. M., Wilman, A. H., et al. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25693 · Cited by 285
Sulzer, D., Cassidy, C., Horga, G., Kang, U. J., Fahn, S., Casella, L., Pezzoli, G., Langley, J. A., Hu, X. P., Zucca, F. A., et al. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-018-0047-3 · Cited by 288
The role of metallobiology and amyloid-β peptides in Alzheimer's disease
Roberts, B. R., Ryan, T. M., Bush, A. I., Masters, C. L., & Duce, J. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07500.x · Cited by 266
Zecca, L., Zucca, F. A., Wilms, H., & Sulzer, D. L. (2003) · Trends in Neurosciences · doi:10.1016/j.tins.2003.08.009 · Cited by 265
The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases
Dušek, P., Roos, P. M., Litwin, T., Schneider, S. A., Flaten, T. P., & Aaseth, J. (2014) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2014.05.007 · Cited by 260
Labandeira-García, J. L., Rodriguez-Perez, A. I., Garrido‐Gil, P., Rodríguez‐Pallares, J., Lanciego, J. L., & Guerra, M. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00129 · Cited by 259
Yokel, R. A. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-102-309 · Cited by 246
Weinreb, O., Amit, T., Mandel, S. A., & Youdim, M. B. H. (2009) · Genes & Nutrition · doi:10.1007/s12263-009-0143-4 · Cited by 244
Neuromelanin of the Human Substantia Nigra: An Update
Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L., & Zecca, L. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9435-y · Cited by 243
Miller, C. L., Llenos, I. C., Dulay, J. R., & Weis, S. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.056 · Cited by 243
Brain iron metabolism: Neurobiology and neurochemistry
Ke, Y., & Qian, Z. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.07.009 · Cited by 239
Faucheux, B. A., Martin, M., Beaumont, C., Hauw, J., Agid, Y., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01923.x · Cited by 229
NCOA4-Mediated Ferritinophagy: A Potential Link to Neurodegeneration
Quiles del Rey, M., & Mancias, J. D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00238 · Cited by 227
Berg, D., Youdim, M. B. H., & Riederer, P. F. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0976-5 · Cited by 221
Zecca, L., Berg, D., Arzberger, T., Ruprecht, P., Rausch, W. D., Musicco, M., Tampellini, D., Riederer, P., Gerlach, M., & Becker, G. (2005) · Movement Disorders · doi:10.1002/mds.20550 · Cited by 214
Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease
Jakaria, M., Belaidi, A. A., Bush, A. I., & Ayton, S. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15519 · Cited by 212
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.
Zecca, L., Tampellini, D., Gerlach, M., Riederer, P. F., Fariello, R. G., & Sulzer, D. L. (2001) · Europe PMC (PubMed Central) · doi:10.1136/mp.54.6.414 · Cited by 200
Decreased transferrin receptor expression by Neuromelanin cells in restless legs syndrome
Connor, J. R., Wang, X. S., Patton, S. M., Menzies, S. L., Troncoso, J. C., Earley, C. J., & Allen, R. P. (2004) · Neurology · doi:10.1212/01.wnl.0000123251.60485.ac · Cited by 199
Age, gender, and hemispheric differences in iron deposition in the human brain: An in vivo MRI study
Xu, X., Wang, Q., & Zhang, M. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.11.017 · Cited by 194
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators
Weinreb, O., Mandel, S. A., Youdim, M. B. H., & Amit, T. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.017 · Cited by 199
Iron metabolism in Parkinsonian syndromes
Berg, D., & Hochstrasser, H. (2006) · Movement Disorders · doi:10.1002/mds.21020 · Cited by 185
Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease
Isaias, I. U., Trujillo, P., Summers, P. E., Marotta, G., Mainardi, L. T., Pezzoli, G., Zecca, L., & Costa, A. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00196 · Cited by 186
Liu, Y., & Simon, J. D. (2003) · Pigment Cell Research · doi:10.1046/j.1600-0749.2003.00098.x · Cited by 185
Iron-binding characteristics of neuromelanin of the human substantia nigra
Double, K. L., Gerlach, M., Schünemann, V., TRAUTWEIN, A. X., Zecca, L., Gallorini, M., Youdim, M. B. H., Riederer, P. F., & Ben‐Shachar, D. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00293-4 · Cited by 182
Ishii, T., Warabi, E., & Mann, G. E. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.002 · Cited by 181
Iron dysregulation in movement disorders
Dušek, P., Jankovic, J. J., & Le, W. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.054 · Cited by 175
Proteome analysis of human substantia nigra in Parkinson's disease
Werner, C. J., Haußen, R. H., Mall, G., & Wolf, S. (2008) · Proteome Science · doi:10.1186/1477-5956-6-8 · Cited by 170
Ayton, S., & Lei, P. (2014) · BioMed Research International · doi:10.1155/2014/581256 · Cited by 163
Ashraf, A., Clark, M., & So, P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00065 · Cited by 163
Recent developments in the pathology of Parkinson’s disease
Jellinger, K. A. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_33 · Cited by 156
Contrast mechanisms associated with neuromelanin‐MRI
Trujillo, P., Summers, P. E., Ferrari, E., Zucca, F. A., Sturini, M., Mainardi, L. T., Cerutti, S., Smith, A. K., Smith, S. A., Zecca, L., et al. (2016) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26584 · Cited by 154
Ion‐Exchange and Adsorption of Fe(III) by Sepia Melanin
Liu, Y., Hong, L., Kempf, V. R., Wakamatsu, K., Ito, S., & Simon, J. D. (2004) · Pigment Cell Research · doi:10.1111/j.1600-0749.2004.00140.x · Cited by 153
Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies
Ma, L., Azad, M. G., Dharmasivam, M., Richardson, V., Quinn, R. J., Feng, Y., Pountney, D. L., Tonissen, K. F., Mellick, G. D., Yanatori, I., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101896 · Cited by 151
Iron Homeostasis Disorder and Alzheimer’s Disease
Peng, Y., Chang, X., & Lang, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212442 · Cited by 146
Charkoudian, L. K., & Franz, K. J. (2006) · Inorganic Chemistry · doi:10.1021/ic060014r · Cited by 147
Jeong, S. Y., & David, S. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.2922-06.2006 · Cited by 149
Iron overload: Effects on cellular biochemistry
Nogueira, L. S., Oliveira, M. M., Pessoa, M. T., & Barbosa, L. A. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.11.029 · Cited by 149
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Schneider, S. A., Dušek, P., Hardy, J., Westenberger, A., Jankovic, J. J., & Bhatia, K. P. (2013) · Current Neuropharmacology · doi:10.2174/157015913804999469 · Cited by 140
Iron, the substantia nigra and related neurological disorders
Snyder, A. M., & Connor, J. R. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.08.005 · Cited by 138
Structure and function of amyloid in Alzheimer's disease
Morgan, C., Colombres, M., Núñez, M. T., & Inestrosa, N. C. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.10.004 · Cited by 146
The Neuromelanin of Human Substantia Nigra: Physiological and Pathogenic Aspects
Zucca, F. A., Giaveri, G., Gallorini, M., Albertini, A., Toscani, M., Pezzoli, G., Lucius, R., Wilms, H., Sulzer, D. L., Ito, S., et al. (2004) · Pigment Cell Research · doi:10.1111/j.1600-0749.2004.00201.x · Cited by 134
Zucca, F. A., Bellei, C., Giannelli, S. G., Terreni, M., Gallorini, M., Rizzio, E., Pezzoli, G., Albertini, A., & Zecca, L. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0453-2 · Cited by 132
Aluminum’s Involvement in the Progression of Alzheimer’s Disease
Walton, J. R. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121909 · Cited by 128
Genoud, S., Roberts, B. R., Gunn, A. P., Halliday, G. M., Lewis, S. J. G., Ball, H. J., Hare, D. J., & Double, K. L. (2017) · Metallomics · doi:10.1039/c7mt00244k · Cited by 126
Liu, Y., Kempf, V. R., Nofsinger, J. B., Weinert, E. E., Rudnicki, M. D., Wakamatsu, K., Ito, S., & Simon, J. D. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00059.x · Cited by 126
Metal imaging in neurodegenerative diseases
Bourassa, M. W., & Miller, L. M. (2012) · Metallomics · doi:10.1039/c2mt20052j · Cited by 125
Xu, Q., Kanthasamy, A. G., & Reddy, M. B. (2007) · Toxicology · doi:10.1016/j.tox.2007.12.017 · Cited by 121
Chen, H., Lukas, T. J., Du, N. Y., Suyeoka, G. M., & Neufeld, A. H. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2850 · Cited by 120
Role of iron in neurodegenerative diseases
Li, K., & Reichmann, H. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1508-7 · Cited by 121
Insights into Melanosomes and Melanin from Some Interesting Spatial and Temporal Properties
Simon, J. D., Hong, L., & Peles, D. N. (2008) · The Journal of Physical Chemistry B · doi:10.1021/jp804248h · Cited by 119
Modifications of the iron–neuromelanin system in Parkinson's disease
Fasano, M., Bergamasco, B., & Lopiano, L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03638.x · Cited by 117
Iron and reactive oxygen species activity in parkinsonian substantia nigra
del Nogal, A. W., Gałązka-Friedman, J., Bauminger, E. R., Wszołek, Z. K., Schweitzer, K. J., Dickson, D. W., Jaklewicz, A., Elbaum, D., & Friedman, A. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.02.007 · Cited by 117
Faucheux, B. A., Martin, M., Beaumont, C., Hunot, S., Hauw, J., Agid, Y., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01118.x · Cited by 116
Zhang, X., Thompson, M., & Xu, Y.-H. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.161 · Cited by 116
Cheng, Z., He, N., Huang, P., Li, Y., Tang, R., Sethi, S. K., Ghassaban, K., Yerramsetty, K. K., Palutla, V. K., Chen, S., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.102103 · Cited by 115
Gerlach, M., Double, K. L., Ben‐Shachar, D., Zecca, L., Youdim, M. B. H., & Riederer, P. F. (2003) · Neurotoxicity Research · doi:10.1007/bf03033371 · Cited by 112
Using High-Resolution MR Imaging at 7T to Evaluate the Anatomy of the Midbrain Dopaminergic System
Eapen, M., Zald, D. H., Gatenby, J. C., Ding, Z., & Gore, J. C. (2010) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2355 · Cited by 109
Suh, J., Moreau, R., Heath, S.-H. D., & Hagen, T. (2005) · Redox Report · doi:10.1179/135100005x21624 · Cited by 107
Brain iron accumulation in aging and neurodegenerative disorders
Hagemeier, J., Geurts, J. J. G., & Zivadinov, R. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.128 · Cited by 114
The Involvement of Iron in Traumatic Brain Injury and Neurodegenerative Disease
Daglas, M., & Adlard, P. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00981 · Cited by 114
Common and Trace Metals in Alzheimer’s and Parkinson’s Diseases
Doroszkiewicz, J., Farhan, J. A., Mroczko, J., Winkel, I., Perkowski, M., & Mroczko, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115721 · Cited by 108
Impaired iron status in aging research
Xu, J., Jia, Z., Knutson, M. D., & Leeuwenburgh, C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13022368 · Cited by 103
Life span pigmentation changes of the substantia nigra detected by neuromelanin‐sensitive MRI
Xing, Y., Sapuan, A. H., Dineen, R. A., & Auer, D. P. (2018) · Movement Disorders · doi:10.1002/mds.27502 · Cited by 105
The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System
Joppe, K., Roser, A., Maass, F., & Lingor, P. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00015 · Cited by 103
Iron Metabolism in Aging and Age-Related Diseases
Tian, Y., Tian, Y., Yuan, Z., Zeng, Y., Wang, S., Fan, X., Yang, D., & Yang, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073612 · Cited by 110
Influence of neuromelanin on oxidative pathways within the human substantia nigra
Double, K. L., Ben-Shachar, D., Youdim, M. B. H., Zecca, L., Riederer, P., & Gerlach, M. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00218-0 · Cited by 102
Genetics of iron regulation and the possible role of iron in Parkinson's disease
Rhodes, S. L., & Ritz, B. R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.07.001 · Cited by 103
Iron in neurodegenerative disorders
Berg, D., Becker, G., Riederer, P. F., & Rieß, O. (2002) · Neurotoxicity Research · doi:10.1080/1029842021000045444 · Cited by 98
Disturbance of iron metabolism in Parkinson’s disease — ultrasonography as a biomarker
Berg, D., Hochstrasser, H., Schweitzer, K. J., & Rieß, O. (2006) · Neurotoxicity Research · doi:10.1007/bf03033302 · Cited by 98
Dopamine efflux by MPTP and hydroxyl radical generation
Obata, T. (2002) · Journal of Neural Transmission · doi:10.1007/s00702-001-0683-2 · Cited by 96
Andreas Schäfer, A., Forstmann, B. U., Neumann, J., Wharton, S., Mietke, A., Bowtell, R. W., & Turner, R. (2011) · Human Brain Mapping · doi:10.1002/hbm.21404 · Cited by 96
Wise, R. M., Wagener, A., Fietzek, U. M., Klopstock, T., Mosharov, E. V., Zucca, F. A., Sulzer, D., Zecca, L., & Burbulla, L. F. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105920 · Cited by 96
Feng, S.-T., Wang, Z.-Z., Yuan, Y.-H., Sun, H.-M., Chen, N.-H., & Zhang, Y. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104336 · Cited by 96
Lü, L., Qian, Z., Wu, K.-C., Yung, W., & Ke, Y. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0067-0 · Cited by 92
Book Review: Iron and Parkinson’s Disease
Wolozin, B. L., & Golts, N. (2002) · The Neuroscientist · doi:10.1177/107385840200800107 · Cited by 89
Metadata
- Authors
- Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., Vezzoni, P., & Tampellini, D.
- Affiliations
- Institute of Biomedical Technologies (IT)
- University of Pavia (IT)
- University of Lübeck (DE)
- University of Würzburg (DE)
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2001-03-15
- Volume
- 76
- Issue
- 6
- Pages
- 1766-1773
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1601438958
- Cited by
- 401
- References
- 61
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 11 · 2023: 13 · 2022: 19 · 2021: 25 · 2020: 13 · 2019: 20 · 2018: 23 · 2017: 18 · 2016: 19 · 2015: 10 · 2014: 14 · 2013: 17 · 2012: 14
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Fondazione Cariplo
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- brain iron, substantia nigra, neuromelanin, ferritin, iron storage, aging, neurodegeneration, high-spin iron, postmortem brain
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Aging, Child, Child, Preschool, Ferritins, Humans, Infant, Iron, Melanins, Middle Aged, Nerve Degeneration, Reference Values, Substantia Nigra
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review